Cellectis announced it will present Phase 1 clinical trial data for its CAR-T therapies lasme-cel and eti-cel at the European Hematology Association (EHA) congress in June 2026. Lasme-cel showed promising safety and response rates in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia, supporting ongoing Phase 2 trials. Eti-cel data from a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma will also be presented, offering insights into treatment optimization. Interim Phase 2 results for lasme-cel and full Phase 1 data for eti-cel are expected later in 2026, marking important steps toward potential new therapies for difficult-to-treat blood cancers.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
Lockheed Martin Ventures, the $1 billion venture capital arm of Lockheed Martin, is expanding into the UK and Europe with a new London office. It plans to invest at least $100 million in defense technology startups to strengthen transatlantic defense...
